Clinical trialNCT04358393UnknownPhase 1/PHASE2Interventional

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

SponsorAscentage Pharma Group Inc.Enrollment69AMLAcute Myeloid LeukemiaCMMLChronic Myelomonocytic LeukemiaHigh-risk Myelodysplastic SyndromeMDS+1 more conditions

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Yifan Zhai, MD, PhD
Ascentage Pharma Group Inc.
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
Matthew Ulrickson, MD
Recruiting
Rocky Mountain Cancer Centers
Denver, Colorado, United States
Christopher Benton, MD
Recruiting
Duke University
Durham, North Carolina, United States
Harry Erba, MD, PhD
Recruiting
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Moshe Levy, MD
Recruiting
Md Anderson
Houston, Texas, United States
Tapan Kadia, MD
Recruiting
Texas Oncology - Tyler
Tyler, Texas, United States
Habte Yimer, MD
Recruiting
Virginia Cancer Specialists
Fairfax, Virginia, United States
Mitul Gandhi, MD
Recruiting
Seattle Cancer Care Alliance
Seattle, Washington, United States
Mary-Elizabeth Percival, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azacitidine →Alrizomadlin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 4 Dec 2020
Primary completion: 30 Dec 2024
Completion: 30 Dec 2025
Last update posted: 1 Feb 2024
Registered enrollment: 69
Registry id: NCT04358393

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.